M&A Deal Summary |
|
|---|---|
| Date | 2006-11-16 |
| Target | Conor Medsystems |
| Sector | Medical Products |
| Buyer(s) | Johnson & Johnson |
| Sellers(s) | Easton Capital Investment Group |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.4B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1886 |
| Sector | Consumer Products |
| Employees | 132,000 |
| Revenue | 88.8B USD (2024) |
Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 47 |
| Sector: Medical Products M&A | 10 of 17 |
| Type: Add-on Acquisition M&A Deals | 12 of 39 |
| State: California M&A | 6 of 15 |
| Country: United States M&A | 15 of 39 |
| Year: 2006 M&A | 3 of 3 |
| Size (of disclosed) | 16 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-06-26 |
Pfizer Consumer Healthcare
Berlin, Germany Pfizer Consumer Healthcare GmbH global business of personal care and over-the-counter (OTC) products. A leading brands include LISTERINE oral care products and the NICORETTE line of smoking cessation treatments. Other widely recognized and trusted brands include LUBRIDERM, VISINE, NEOSPORIN, SUDAFED, ZANTAC and BENADRYL. |
Buy | $16.6B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-06-18 |
Amic AB
Uppsala, Sweden Amic is a privately held Swedish developer of in vitro diagnostic (IVD) technologies for use in Point-of-Care (POC) and near-patient settings (outside the physical facilities of the clinical laboratory). |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 200M USD |
| Size | Small |
| Type | Sector Focused |
Easton Capital Investment Group is a private investment firm that targets early-stage venture capital to later-stage growth capital investments. Easton will consider opportunities across a range of industries but generally invests in the healthcare industry, including biopharmaceuticals, drug delivery, medical devices, and healthcare services. Easton looks to commit $0.50 to $10 million per transaction. Easton Capital was formed in 2000 and is based in New York, New York.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 21 |
| Sector: Medical Products M&A | 2 of 4 |
| Type: Add-on Acquisition M&A Deals | 3 of 9 |
| State: California M&A | 3 of 6 |
| Country: United States M&A | 7 of 21 |
| Year: 2006 M&A | 3 of 3 |
| Size (of disclosed) | 1 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-04-01 |
Targacept
Winston-Salem, North Carolina, United States Targacept is a R&D pharmaceutical company. Targacept is involved with the development and commercialization of drugs based on selective activation of a previously unexploited class of targets - neuronal nicotinic acetylcholine receptors (NNRs). These drugs offer a new way to treat various major CNS and gastrointestinal diseases and disorders including Alzheimer's Disease, depression and ulcerative colitis. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
Quasar
Albuquerque, New Mexico, United States Quasar is an established leader in Ultrasonic Resonant Inspection, an emerging technology in the field of non-destructive inspection (NDI) using sophisticated pattern-recognition software to analyze ultrasonic resonance measurements on the item being inspected. Quasar was acquired by Illinois Tool Works in 2007, generating proceeds to Easton 2.4x its initial cost. |
Sell | - |
